HC Wainwright Has Negative Estimate for CareDx Q1 Earnings

CareDx, Inc (NASDAQ:CDNA) – Analysts at HC Wainwright lowered their Q1 2025 EPS estimates for shares of CareDx in a research report issued to clients and investors on Monday, March 3rd. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.21) per share for the quarter, down from their prior estimate of ($0.12). HC Wainwright currently has a “Neutral” rating and a $25.00 price target on the stock. The consensus estimate for CareDx’s current full-year earnings is ($0.90) per share. HC Wainwright also issued estimates for CareDx’s Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.50) EPS.

Several other research firms have also issued reports on CDNA. Wells Fargo & Company upgraded shares of CareDx from an “underweight” rating to an “equal weight” rating and cut their price target for the company from $28.00 to $24.00 in a research report on Wednesday, January 15th. Stephens reaffirmed an “overweight” rating and set a $40.00 price objective on shares of CareDx in a research note on Thursday, February 27th. Finally, StockNews.com raised shares of CareDx from a “hold” rating to a “buy” rating in a research note on Wednesday, February 26th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, CareDx presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.83.

CareDx Stock Performance

Shares of NASDAQ:CDNA opened at $20.42 on Thursday. CareDx has a 52-week low of $7.42 and a 52-week high of $34.84. The firm has a fifty day moving average of $22.67 and a 200 day moving average of $25.05. The firm has a market capitalization of $1.10 billion, a PE ratio of -7.56 and a beta of 1.87.

CareDx (NASDAQ:CDNA) last issued its earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $1.46. The business had revenue of $86.58 million for the quarter, compared to analysts’ expectations of $84.56 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%.

Institutional Investors Weigh In On CareDx

A number of institutional investors have recently made changes to their positions in CDNA. Quarry LP purchased a new stake in shares of CareDx during the third quarter valued at approximately $27,000. Sterling Capital Management LLC grew its holdings in shares of CareDx by 771.2% during the fourth quarter. Sterling Capital Management LLC now owns 1,272 shares of the company’s stock valued at $27,000 after buying an additional 1,126 shares during the last quarter. Harvest Fund Management Co. Ltd purchased a new stake in shares of CareDx during the third quarter valued at approximately $52,000. Tower Research Capital LLC TRC grew its holdings in shares of CareDx by 553.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company’s stock valued at $84,000 after buying an additional 3,322 shares during the last quarter. Finally, State of Wyoming purchased a new stake in shares of CareDx during the fourth quarter valued at approximately $91,000.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.